Compare EQ & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQ | BCIC |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.4M | 74.1M |
| IPO Year | 2018 | 2006 |
| Metric | EQ | BCIC |
|---|---|---|
| Price | $1.28 | $5.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $8.56 | ★ $9.83 |
| AVG Volume (30 Days) | ★ 312.5K | 75.5K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 20.00% |
| EPS Growth | N/A | ★ 262.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,095,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $5.36 |
| 52 Week High | $6.20 | $13.44 |
| Indicator | EQ | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 30.70 |
| Support Level | $1.24 | N/A |
| Resistance Level | $1.51 | $7.62 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 15.79 | 0.26 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
BCP Investment Corp is an externally managed, non-diversified closed-end investment company. The company invests in secured term loans, bonds or notes and mezzanine debt in privately-held middle market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt and selected equity investments in privately-held middle market companies.